AIM: The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.

METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

STRUCTURE: Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.

目的：“2023 ACC/AHA/ACCP/HRS房颤诊断和管理指南”为指导临床医生治疗房颤患者提供了建议。

方法：从2022年05月12日至2022年11月03日进行了全面的文献检索，包括PubMed、EMBASE、Cochrane Librar

y、医疗保健研究和质量，以及与本指南相关的其他选定数据库。指南撰写过程中，撰写委员会还考虑了截至2022年11月发表的其他相关研究，并在适当情况下将其添加到证据表中。

结构：房颤是最常见的持续性心律失常，其发病率和患病率在美国和全球范围内呈上升趋势。“2014年 AHA/ACC/HRS 房颤患者管理指南”和“2019年 AHA/ACC/HRS房颤患者管理指南重点更新”中的建议已更新为新证据，以指导临床医生。此外，针对房颤和血栓栓塞风险评估、抗凝、左心耳封堵、房颤导管或外科消融、风险因素调整和房颤预防提出了新建议。